The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics.
Conflicting conclusions have been reported about interaction of calcium channel blockers with digoxin. The effects of verapamil (240 mg/day) and a new dihydropyridine calcium channel blocker, isradipine (15 mg/day), on the pharmacokinetics of 1 mg intravenous digoxin were compared. All 24 volunteer subjects were healthy, male, nonobese, and aged 18 to 38 years. Groups of 12 subjects received each oral agent over 15 days, with collections of blood and urine for 72 hours after intravenous digoxin. Significant (P less than 0.05) reduction in nonrenal (7.01 +/- 1.97 to 4.00 +/- 1.86 L/hr) and total clearance (14.1 +/- 2.6 to 11.5 +/- 2.5 L/hr) were induced by verapamil, without change in renal clearance. A near-significant (P less than 0.1) increase in peripheral volume of distribution contributed to prolonged elimination half-life (23.1 +/- 4.4 to 34.3 +/- 9.7 hours). By contrast, isradipine caused only a 9% reduction in volume of distribution. Verapamil causes digoxin accumulation by reducing nonrenal elimination. No evidence of clinically relevant interaction of isradipine with digoxin was seen.
D000293:Adolescent; D000328:Adult; D004077:Digoxin / Q000097:blood / Q000378:metabolism*; D004347:Drug Interactions; D006801:Humans; D017275:Isradipine; D007700:Kinetics; D008297:Male; D011725:Pyridines / Q000494:pharmacology*; D011897:Random Allocation; D014700:Verapamil / Q000494:pharmacology*
D011725:Pyridines; D004077:Digoxin; D014700:Verapamil; D017275:Isradipine